Sol-Gel Technologies Ltd. Stock

Equities

SLGL

IL0011417206

Biotechnology & Medical Research

Market Closed - Nasdaq 16:30:01 2024-04-26 EDT 5-day change 1st Jan Change
0.8896 USD +3.32% Intraday chart for Sol-Gel Technologies Ltd. -5.36% -19.49%
Sales 2024 * 2.4M 3.28M Sales 2025 * 6.1M 8.34M Capitalization 24.78M 33.87M
Net income 2024 * -19M -25.97M Net income 2025 * -14M -19.14M EV / Sales 2024 * 10.3 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 4.06 x
P/E ratio 2024 *
-1.27 x
P/E ratio 2025 *
-2.17 x
Employees 36
Yield 2024 *
-
Yield 2025 *
-
Free-Float 34.83%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Sol-Gel Technologies Ltd.

1 day+3.32%
1 week-5.36%
Current month-9.23%
1 month-9.91%
3 months-25.87%
6 months-34.10%
Current year-19.49%
More quotes
1 week
0.86
Extreme 0.8608
0.99
1 month
0.79
Extreme 0.79
1.07
Current year
0.79
Extreme 0.79
1.58
1 year
0.79
Extreme 0.79
4.05
3 years
0.79
Extreme 0.79
14.50
5 years
0.00
Extreme 0
21.00
10 years
0.00
Extreme 0
21.00
More quotes
Managers TitleAgeSince
Founder 62 97-10-27
Director of Finance/CFO 56 17-01-31
Chief Operating Officer 48 09-12-31
Members of the board TitleAgeSince
Director/Board Member 55 23-07-25
Director/Board Member 50 18-09-12
Chairman 69 13-12-31
More insiders
Date Price Change Volume
24-04-26 0.8896 +3.32% 3,068
24-04-25 0.861 -6.41% 92,901
24-04-24 0.92 -0.56% 7,564
24-04-23 0.9252 -1.05% 8,832
24-04-22 0.935 -0.53% 15,611

Delayed Quote Nasdaq, April 26, 2024 at 04:30 pm

More quotes
Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.8896 USD
Average target price
8 USD
Spread / Average Target
+799.28%
Consensus